Abstract
Dementia is a syndrome resulting from chronic or progressive brain disease. Around 40% of worldwide dementia can be prevented or delayed by modifying 12 risk factors: low educational attainment in early life, mid-life hypertension, mid-life obesity, hearing loss, traumatic brain injury, excessive alcohol consumption, smoking, depression, physical inactivity, social isolation, diabetes mellitus, and air pollution. There is growing evidence that gastrointestinal tract microbiota may significantly contribute to dementia pathogenesis. In particular, gut dysbiosis can trigger metabolic diseases and the progression of low-grade systemic inflammation, being involved in much of the major modifiable risk factors. In this review, we focus on studies that have evaluated the association between modifiable risk factors for dementia and the role of gut microbiota. We also suggest clinical implications for researchers in dementia-gut microbiota related fields.
Keywords: Dementia, risk factor, gut microbiota, dysbiosis, lifestyle, prevention.
Current Alzheimer Research
Title:Modifiable Risk Factors for Dementia: The Role of Gut Microbiota
Volume: 18 Issue: 13
Author(s): Cristian Cabrera, Paloma Vicens and Margarita Torrente*
Affiliation:
- Department of Psychology, CRAMC (Research Center for Behavior Assessment), Tarragona,Spain
- Laboratory of Toxicology and Environmental Health, TECNATOX, Institut d’Investigació Sanitària Pere Virgili, Reus, Spain
Keywords: Dementia, risk factor, gut microbiota, dysbiosis, lifestyle, prevention.
Abstract: Dementia is a syndrome resulting from chronic or progressive brain disease. Around 40% of worldwide dementia can be prevented or delayed by modifying 12 risk factors: low educational attainment in early life, mid-life hypertension, mid-life obesity, hearing loss, traumatic brain injury, excessive alcohol consumption, smoking, depression, physical inactivity, social isolation, diabetes mellitus, and air pollution. There is growing evidence that gastrointestinal tract microbiota may significantly contribute to dementia pathogenesis. In particular, gut dysbiosis can trigger metabolic diseases and the progression of low-grade systemic inflammation, being involved in much of the major modifiable risk factors. In this review, we focus on studies that have evaluated the association between modifiable risk factors for dementia and the role of gut microbiota. We also suggest clinical implications for researchers in dementia-gut microbiota related fields.
Export Options
About this article
Cite this article as:
Cabrera Cristian , Vicens Paloma and Torrente Margarita*, Modifiable Risk Factors for Dementia: The Role of Gut Microbiota, Current Alzheimer Research 2021; 18 (13) . https://dx.doi.org/10.2174/1567205018666211215152411
DOI https://dx.doi.org/10.2174/1567205018666211215152411 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Immobilized Using Nanotechnology of Electron-Beam Synthesis Regulators of Progenitor Cells Functions: Remedies of New Generation for Regenerative Medicine
Recent Patents on Regenerative Medicine Glycobiology in Malignant Gliomas: Expression and Functions of Galectins and Possible Therapeutic Options
Current Pharmaceutical Biotechnology The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition Identifying the Characteristics of the Hypusination Sites Using SMOTE and SVM Algorithm with Feature Selection
Current Proteomics Vascular Injury During Elevated Glucose can be Mitigated by Erythropoietin and Wnt Signaling
Current Neurovascular Research Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurologic Disorders and Prostate Cancer
Current Medicinal Chemistry The Main Receptors Involved in the COVID-19: A Systematic Review and Meta-Analysis
Current Medicinal Chemistry Glycodendrimer PPI as a Potential Drug in Chronic Lymphocytic Leukaemia. The Influence of Glycodendrimer on Apoptosis in In Vitro B-CLL Cells Defined by Microarrays
Anti-Cancer Agents in Medicinal Chemistry Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17β-Estradiol Treatment
Current Neurovascular Research Regulation of Oxidative Stress and Cardioprotection in Diabetes Mellitus
Current Cardiology Reviews Erlotinib Hydrochloride Novel Drug Delivery Systems: A Mini Review Unravelling the Role of Micro- and Nanocarriers
Drug Delivery Letters Sweet and Sour - Oxidative and Carbonyl Stress in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Erythropoietin: New Approaches to Improved Molecular Designs and Therapeutic Alternatives
Current Pharmaceutical Design The Role of Matrix Metalloproteinase Inhibitors in Ischemia-Reperfusion Injury in the Liver
Current Pharmaceutical Design Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Cytokines in the Central Nervous System: Targets for Therapeutic Intervention
Current Drug Targets - CNS & Neurological Disorders Neurotrophic Factors - A Tool for Therapeutic Strategies in Neurological,Neuropsychiatric and Neuroimmunological Diseases?
Current Medicinal Chemistry Targeting the Cancer-Stroma Interaction: A Potential Approach for Pancreatic Cancer Treatment
Current Pharmaceutical Design